Role of PET in the Initial Staging of Cutaneous Malignant Melanoma: Systematic Review
Authors:
- Ralph CrottRCRalph Crott
- Max LonneuxMLMax Lonneux
- Jean-François BaurainJBJean-François Baurain
- Anne-Sophie PirsonAPAnne-Sophie Pirson
- Thierry Vander BorghtTBThierry Vander Borght
- 1 December 2008
- journal article
- research article
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 249 (3) , 836-844
Abstract
To calculate summary estimates of the diagnostic performance of fluorine 18 fluorodeoxyglucose (FDG) positron emission tomographic (PET) imaging in the initial staging of cutaneous malignant melanoma (CMM), following the new American Joint Committee on Cancer (AJCC) staging classification on per-patient and per-lesion bases. MEDLINE, EMBASE, Web of Science, and Cochrane Database of Systematic Reviews databases, and reference lists of reviews and included papers were searched, without any language restrictions, for relevant articles published before March 2007. Two reviewers independently assessed study eligibility and methodologic quality by using the quality assessment of diagnostic accuracy studies checklist. A pooled random effect was estimated and a fixed coefficient regression model was used to explore the existing heterogeneity. Twenty-eight studies involving 2905 patients met the inclusion criteria. The pooled estimates of FDG PET for the detection of metastasis in the initial staging of CMM were sensitivity, 83% (95% confidence interval [CI]: 81%, 84%); specificity, 85% (95% CI: 83%, 87%); positive likelihood ratio (LR), 4.56 (95% CI: 3.12, 6.64); negative LR, 0.27 (95% CI: 0.18, 0.40); and diagnostic odds ratio, 19.8 (95% CI: 10.8, 36.4). Results from eight studies suggested that FDG PET was associated with 33% disease management changes (range, 15%-64%). There is good preliminary evidence that FDG PET is useful for the initial staging of patients with CMM, especially as adjunctive role in AJCC stages III and IV, to help detect deep soft-tissue, lymph node, and visceral metastases. FDG PET-computed tomographic imaging seemed to be more precise than PET alone, as suggested by four eligible studies. Further evaluation by using a well-designed prospective study, with clinical outcome-focused measures and cost effectiveness analysis, is needed to clarify the appropriate role of FDG PET in CMM staging. http://radiology.rsnajnls.org/cgi/content/full/249/3/836/DC1.Keywords
This publication has 80 references indexed in Scilit:
- F-18 fluorodeoxy-D-glucose positron emission tomography scan in the initial evaluation of patients with a primary melanoma thicker than 4 mmMelanoma Research, 2007
- Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanomaEuropean Journal of Cancer, 2007
- Novel Imaging Techniques in MelanomaSurgical Oncology Clinics of North America, 2006
- Impact of [18F]fluorodeoxyglucose positron emission tomography on surgical management of melanoma patientsBritish Journal of Surgery, 2006
- Malignant Melanoma: PET/CT as a Staging Procedure2005
- Baseline staging in cutaneous malignant melanomaBritish Journal of Dermatology, 2004
- Measuring inconsistency in meta-analysesBMJ, 2003
- Primary staging and follow-up of high risk melanoma patients with whole-body18F-fluorodeoxyglucose positron emission tomographyCancer, 1999
- Positron emission tomography in the detection and management of metastatic melanomaMelanoma Research, 1996
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986